Cancer Family
Mesothelial Neoplasm
CI-CAN-00000028Explore in graph →
Non-malignant108 active trials4 approved drugs13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000028Explore in graph →
Clinical trials
521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07824986 | A Phase 3 Trial in Advanced Epithelioid Mesothelioma(sTEADfast) | not yet recruiting | Phase 3 | 350 | Vivace Therapeutics, IncINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | not yet recruiting | Phase 1 | 120 | Treeline Biosciences, Inc.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07602946 | SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma(SELECTmeso) | not yet recruiting | Phase 2 | 30 | University of SouthamptonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07550049 | Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology(COMETH) | not yet recruiting | — | 110 | University of Kansas Medical CenterOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT07514793 | Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma | not yet recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07420010 | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. | not yet recruiting | Early Phase 1 | 24 | Weijia Fang, MDOTHER | 0 | Feb 19, 2026 | clinicaltrials |
| NCT07282873 | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 219 | TYK Medicines, IncINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07131345 | Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma | not yet recruiting | Phase 1 / Phase 2 | 55 | National Cancer Center, ChinaOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06416930 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | not yet recruiting | Phase 2 | 59 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | not yet recruiting | Phase 2 | 63 | Oncotelic Inc.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05698238 | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours(CAMP1) | not yet recruiting | Phase 1 | 50 | Mabpro, a.s.INDUSTRY | 0 | Mar 15, 2023 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials